TNFRSF8 and Hodgkins lymphoma: Studies with CAR-T cells against CD30 frequently treated also or mostly patients with Hodgkin’s lymphoma but as adverse events in CAR-Ts in general are more product-specific than disease-specific, the safety data are most probably relevant for T-cell non-Hodgkin’s lymphomas as well.